Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01773811 · ClinicalTrials.gov registry record · NA
Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD
A NA study, sponsored by University of Mississippi, Oxford.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT01773811: Completed NA study, sponsored by University of Mississippi, Oxford.
NCT01773811 is a NA study that has completed, run by University of Mississippi, Oxford. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01773811, a NA study, has completed, sponsored by University of Mississippi, Oxford.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The current study proposes to directly measure how processing after participating in written disclosure about a traumatic life event affects physical and psychological outcomes.
Interventions
- BEHAVIORAL Narrative Writing: Trauma-Assigned
- BEHAVIORAL Narrative Writing: Trauma-Spontaneous
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-05 |
| Phase | NA |
What the finished NCT01773811 record still lists
NCT01773811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Narrative Writing: Trauma-Assigned is the first listed.
NCT01773811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01773811 about?
NCT01773811 is a clinical study titled "Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD". The current study proposes to directly measure how processing after participating in written disclosure about a traumatic life event affects physical and psychological outcomes.
What is the current status of trial NCT01773811?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2012-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01773811?
The interventions under investigation include: Narrative Writing: Trauma-Assigned (BEHAVIORAL), Narrative Writing: Trauma-Spontaneous (BEHAVIORAL).
Who is sponsoring clinical trial NCT01773811?
This trial is sponsored by University of Mississippi, Oxford, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01773811's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia